TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cardiovascular disease
Endpoint domain: Mortality/survival
Primary endpoint: Hypertensive event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid Intimal Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathological complete tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neurological Deficit Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biological responses (changes in bowel sounds, heart rate, airway resistance, bowel movement occurrence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biological responses (changes in bowel sounds, heart rate, airway resistance, bowel movement occurrence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biological responses (changes in bowel sounds, heart rate, airway resistance, bowel movement occurrence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in serum cytokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attention and Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: squalene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non-cholesterol sterols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: grade≥ 2 overall late rectal
Endpoint domain: Adverse events/effects
Primary endpoint: Child overweight and obesity prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure Flow Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early prediction of disease relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean automated office systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity of NM-IL-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calculated Blood Loss at 3rd Post Operative Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total motile sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: progressive motile sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in weekly steps walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of R406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerable Apneic Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI at the final follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS back pain score at the final follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS leg pain score at the final follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline and number of subjects outside the normal range for blood pressure, heart rate, temperature, electrocardiography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in clinical chemistry and haematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epstein-Barr Virus viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade 3/5 acute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: OS-2 year
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Treatment-Related Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: exercise pulmonary arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise pulmonary wedge pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Total Learning and Delayed Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Speed of needle tip placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of needle tip placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in normalized EMG amplitude (%EMGmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in median power frequency (Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Satisfactory Fetal Echocardiography Views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of first biologic
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of anastomotic leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a PASI 90 at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of depressive symptoms (HADS-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sum scores of UPDRS Part III (motor examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HADS subscores (anxiety and depression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotracheal intubation during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1c at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin A1c at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by Clinical-Administered Dissociative Symptoms Scale (CADSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by 4-items positive symptoms subscale of Brief Psychiatric Rating Scale (BPRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by body temperature (oral measurements)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by blood pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by respiration rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events assessed by pulse
Endpoint domain: Adverse events/effects
Primary endpoint: Objective and subjective mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition (electronic Stroop test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MATRICS Consensus Cognitive Battery (MCCB) overall composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Functioning Scale: mean of Role and Social ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Brain-derived neurotrophic factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction Rate of Inpatient Occupational Therapy Session
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary Function Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sleep motor consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the insulin concentration-time curve from 0 to 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change from baseline in self-care with the PEDI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in functional mobility with the Functional Mobility Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in functional mobility with the Mobility Questionnaire47
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of hospitalization due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: stability of High Frequency Tidal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stability of CO2 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of needed manual adjustments on the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fetal biometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subcutaneous abdominal, thigh, and arm adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: newborn body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with timing, content, and delivery of PCPI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Acute Panic Inventory (API)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distance of trachea carina to endotracheal tube tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum Levels of Total Lycopene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Treg cells in the endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of pinopodes in the endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of 32P BioSiliconTM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent change in Fractional Clearance Rate of apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biodistribution of 124IAZGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: human dosimetry data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wholebody MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Desaturation Incidences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in extracellular potassium values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Hemoglobin A1c Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Maximal Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Self-Reported Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in problem solving skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in parenting encouragement skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: change in youths' drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Niche thickness measured by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Niche thickness measured by visual evaluation of the surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage (%) pathological Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial Pressure of Carbon Dioxide (CO2) in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peripheral Capillary Oxygen Saturation (SpO^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in PTSD Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood brain barrier impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characteristics during ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Response at Week 32 in Ruxolitinib-Naïve Participants With Splenomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematocrit (Hct) Control Without Phlebotomy at Week 32 in Ruxolitinib-Naïve Participants Without Splenomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hct Control Without Phlebotomy at Week 32 in All Ruxolitinib-Naïve Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hct Control Without Phlebotomy at Week 32 in Ruxolitinib-Resistant or Intolerant Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Responding to Hepatitis B Surface Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Responding to Diphtheria Toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Responding to Tetanus Toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor dimension change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: severe nocturnal hypoglycemias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stage of finger triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequacy of target volume coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of local and loco-regional recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants with Adverse Events (AEs) and by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Injection- Site Reactions, Infusion-Related Reactions, Hypersensitivity and Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Adverse Events (AEs) Leading to Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration time between incision and fetal head delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response rate (RECIST-Criteria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Modified Rush Video-Based Tic Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Physical Performance at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Physiologic Measurements at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Blood Pressure at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Body Composition at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parental Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Child Behavior Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mortality for SARS-CoV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Estradiol (E2) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with pain greater than 3/10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength measurement at masseter and adductor pollicis muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations after administration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAS Victimization Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Behavior Checklist (SBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in Obtaining Resources Scale (EOR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Damage degree of anal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cytokine levels in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Dark Adaptation Rod Intercept Time (RIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of donor lymphocytes given
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: respiratory variation of the plethysmographic waveform of pulse oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease severity (as measured by International Restless Legs Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive daytime sleepiness (as measured by Epworth Sleepiness scale)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total period of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of complications of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events related to immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropsychiatric side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Composite neuropsychiatric/neurocognitive
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate over 50% in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion counts (non-inflammatory and inflammatory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentration of hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 20 IU/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resonance Frequency Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RANKL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of H.pylori gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GSI-measured breast SFA fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rSO2 (cerebral)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Longitudinal Interval Follow-up Evaluation (LIFE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life